Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087458 · ClinicalTrials.gov registry record · Phase 1
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Perceive Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT06087458 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is actively recruiting participants, run by Perceive Biotherapeutics. The registered enrollment target is 60 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT06087458, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is actively recruiting participants, sponsored by Perceive Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Conditions Studied
Interventions
- BIOLOGICAL VOY-101
Study Locations (11)
California
- The Retina Partners - Encino
- Retinal Consultants Medical Group - Sacramento
- Retina Consultants San Diego - San Diego
Texas
- Star Retina - Burleson
- Retina Center of Texas - Southlake
Other
- Rambam Medical Center - Haifa
- Tel-Aviv Sourasky Medical Center, Ophthalmology Division - Tel Aviv
Arizona
- Retina Macula Institute of AZ - Scottsdale
Utah
- University of Utah John A. Moran Eye Center - Salt Lake City
New South Wales
- Sydney Retina Clinic and Day Surgery - Sydney
Victoria
- Cerulea Clinical Trials - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087458
The ClinicalTrials.gov registry entry for NCT06087458 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Perceive Biotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which VOY-101 is the first listed.
NCT06087458 reports 11 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06087458 about?
NCT06087458 is a clinical study titled "Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration". The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
What is the current status of trial NCT06087458?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-21. Estimated completion is 2028-03.
What conditions does trial NCT06087458 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD.
What interventions are being tested in trial NCT06087458?
The interventions under investigation include: VOY-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06087458?
This trial is sponsored by Perceive Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06087458 being conducted?
This trial has 11 study locations across Arizona, California, Texas, Utah, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.